Skip to content
DataLookout
Menu

NCT07923383

An Open-label, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected Cytochrome P450 Substrates

StatusNot Yet Recruiting
PhasePhase 1
SponsorSanofi
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

AUC for CYP isoform specific substrates midazolam, omeprazole, warfarin, caffeine, and metoprolol
Timeframe: At Treatment Period 1 (CYP substrates alone, Day 1) and after 12 weeks of duvakitug (Treatment Period 2, Day 85)
AUClast for CYP isoform specific substrates midazolam, omeprazole, warfarin, caffeine, and metoprolol
Timeframe: At Treatment Period 1 (CYP substrates alone, Day 1) and after 12 weeks of duvakitug (Treatment Period 2, Day 85)

Secondary (7)

Duvakitug serum concentrations: Ctrough
tmax of CYP substrates alone and after duvakitug administration
t1/2 of CYP substrates alone and after duvakitug administration
tlast of CYP substrates alone and after duvakitug administration
Cmax of CYP substrates alone and after duvakitug administration
Show 2 moreShow less
Number of participants with anti-drug antibodies against duvakitug
Number of participants with TEAEs, TESAEs, TEAESIs, and TEAEs leading to permanent study intervention discontinuation

Arms and interventions

DuvakitugExperimental

Subcutaneous injection of duvakitug as per protocol and oral administration of caffeine, metoprolol, midazolam, omeprazole, warfarin and vitamin K as per protocol

Drugs: Duvakitug